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Cannabinoidsplayanimportantroleinactivity-dependentchangesinsynapticactivityandcaninterfereinseveralbrainfunctions,
including responses to aversive stimuli. The regions responsible for their eﬀects, however, are still unclear. Cannabinoid type
1 (CB1) receptors are widely distributed in the central nervous system and are present in the periaqueductal gray (PAG), a
midbrain structure closely involved in responses related to aversive states. Accordingly, exposure to stressful stimuli increases
endocannabinoid (eCB) levels in the PAG, and local administration of CB1 agonists or drugs that facilitate eCB-mediated
neurotransmission produces antinociceptive and antiaversive eﬀects. To investigate if these drugs would also interfere in animal
models that are sensitive to anxiolytic drugs, we veriﬁed the responses to intra-PAG injection of CB1 agonists in rats submitted to
the elevated plus-maze, the Vogel punished licking test, or contextual aversive conditioning model. The drugs induced anxiolytic-
likeeﬀectsinalltests.Thesamewasobservedwiththetransientreceptorpotentialvanilloidtype1(TRPV1)antagonistcapsazepine
andwithcannabidiol, anonpsychotomimeticphytocannabinoid thatproducesanxiolytic-like eﬀectsaftersystemicadministration
in humans and laboratory animals. These results, therefore, suggest that the PAG could be an important site for the antiaversive
eﬀects of cannabinoids.
Copyright © 2009 F. A. Moreira et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cannabis sativa plant has been used for various purposes
since the dawn of civilizations [1, 2], although only in the
middle of twentieth century were its chemical constituents
identiﬁed. Among its major components, there are the
phytocannabinoids cannabinol, cannabidiol (CBD), and Δ9-
tetrahydrocannabinol (Δ9-THC), the latter accounting for
most of cannabis eﬀects [3–5]. The mechanisms of Δ9-
THC eﬀects started to be unveiled in the late 80s, with the
discovery of CB1 receptors [6, 7]. Soon afterwards, the ﬁrst
endogenous agonist (arachidonoyl ethanolamide, AEA) was
isolated and named anandamide, after the Sanskrit word
“ananda” for “bliss” [8]. A second endocannabinoid, 2-
arachidonoylglycerol[9],andanothercannabinoidreceptor,
called CB2 [10], soon followed. Selective antagonists were
developed, such as rimonabant and AM251, supporting the
notion that the CB1 receptor is the major responsible for the
behavioral eﬀects of cannabinoids [11, 12]. The expression
of this receptor is considerably high in several brain regions
such as the basal ganglia, cerebral cortex, hippocampus,
amygdale, hypothalamus, and periaqueductal gray (PAG)
[13, 14].
CB1 receptors are believed to be located in presynap-
tic terminals [15]. They activate Gi proteins that inhibit
adenylate cyclase and calcium channels and enhance potas-
sium currents, thereby reducing neural ﬁring and neuro-
transmitter release [16]. This complements the fact that
endocannabinoids are synthesized on a stimulus-dependent
manner in postsynaptic neurons and immediately diﬀuse to
thesynapticcleft[16].Thus,contrarytoclassicalneurotrans-
mitters, endocannabinoids act “on demand” as retrograde
messengers, inhibiting neural activity. Their eﬀects cease by
internalization followed by hydrolysis in neurons. It is still
controversial whether endocannabinoids move through the
cell membrane passively or are internalized by a putative2 Neural Plasticity
transporter. Although the latter remains to be identiﬁed
[17, 18], pharmacological tools were developed, such as
AM404, which are able to inhibit it and, thereby, increase
CB1 receptor activation by AEA [18]. Inside neurons, AEA
and 2-AG are catabolized by fatty acid amide hydrolase
(FAAH) and monoacyl glycerol lipase (MGL), respectively
[19]. Possibly, FAAH is located in postsynaptic neurons,
whereas MGL is expressed in the presynapse [17]. Selective
inhibitorsofeitherFAAH(URB597)orMGL(URB602)have
been developed, which provide the possibility of enhancing
CB1 receptor activation by increasing the brain levels of
endocannabinoids. Studies with these drugs as well as with
genetically modiﬁed mice have related endocannabinoids to
several functions of the central nervous system (for review,
see [20]).
Other putative components of this system are the
transient receptor potential vanilloid type 1 (TRPV1),
the peroxisome-proliferator activated receptor, and the G
protein-coupled receptor GPR55. Although anandamide
binds to all these receptors, their functions remain uncertain
[21]. In addition, an allosteric site in the CB1 receptor
has been identiﬁed [22] and there is the possibility that,
contrary to the initial thoughts, CB2 receptors may indeed
be relevant for behavioral responses [23, 24]. Finally, more
substances have been proposed as endocannabinoids, such
as arachidonoyl dopamine, virodhamine, and noladin ether
[20].
2.CannabinoidsandAnxiety
Natural or synthetic cannabinoids or CB1 receptor antago-
nists often yield complex responses in experimental models
of anxiety. As summarized in Table 1, several authors have
noticed bell-shaped dose-response curves in animal models
predictive of anxiogenic- or anxiolytic-like activity, namely,
the elevated plus maze (EPM), the elevated zero maze
(EZM), the light dark test (DLT), and the Vogel conﬂict
test (VCT). CB1 receptor agonists tend to be anxiolytic in
lower doses, whereas higher doses may be anxiogenic [25].
However,compoundsthatenhanceendocannabinoideﬀects,
such as inhibitors of AEA uptake or hydrolysis, appear to
produce only anxiolytic eﬀects without bell-shaped dose-
response curves (Table 1).
The reasons for these complex eﬀects remain unknown.
One possibility could be that these drugs would interfere
with diverse brain regions which have diﬀerent roles in the
modulation of anxiety-like responses. However, the sites
responsible for the eﬀects of cannabinoids remain poorly
investigated. CB1 receptors, as well as the putative protein
responsible for internalization of AEA and the enzyme
FAAH, are expressed in several regions of CNS related to
anxiety, aversion, and defensive behaviors, including the
prefrontal cortex, amygdala, hippocampus, hypothalamus,
and PAG [13, 14]. These structures are proposed to be part
of a system responsible for the elaboration of behavioral and
autonomic responses to aversive stimuli. They are possible
neural sites whose malfunction would lead to psychiatric
pathologies such as generalized anxiety and panic disorders
[26]. In this context, anxiolytic drugs would act by normaliz-
ing the functions of these structures [27, 28]. Moreover, this
brain aversive system would be responsible for behavioral
suppression in animal models predictive of anxiolytic-like
activity. Generally, models of experimental anxiety rely
on exposing animals to situation that generates conﬂicts
between approach and avoidance, which can be generated by
the drive of exploring a new, though, aversive environment,
or by a source of reward that is associated with punishment.
Anxiolytic-like drugs injected either systemically or into
these structures shift the conﬂict toward approach responses
[27, 28]. Thus, these models provide invaluable insights
into the neurobiology of anxiety and the pharmacology of
anxiolytic compounds. As discussed below, we have used
direct drug administration in animals submitted to these
models for studying the possible role of the PAG in the
antiaversive actions of cannabinoids.
3. AnxiolyticEffects of Cannabinoidsin
the PeriaqueductalGray
The PAG is a mesencephalic structure that surrounds the
cerebral aqueduct and can be divided along its rostro-
caudal axis into dorsomedial, dorsolateral (dlPAG), lateral,
and ventrolateral columns [29]. It is an important site
in ascending pain transmission and a major component
of a descending pain inhibitory system. Moreover, this
structure receives glutamatergic projection from forebrain
regions and sends descendent pathways to motor outputs
and to autonomic centres that control blood pressure and
heart rate [26]. The dorsal columns (dPAG) are possibly
responsible for the elaboration of active defensive behaviors
(see [26], for review). Lesions of the dPAG inhibit fear and
anxiety produced by stimulation of the amygdala whereas
stimulation of this region induces threat display associated
with vocalization and strong ﬂight responses [26]. In the
caudal ventrolateral PAG, however, immobility has been
described as the main outcome of local stimulation [30].
CB1 receptors are distributed along the various columns
of this structure [13]. Moreover, administration of CB1
agonists increases Fos expression [31] and brain metabolic
activity in the PAG of rats [32], suggesting that this structure
could be involved in the eﬀects of systemically administered
cannabinoids. In agreement with this proposal, injection
of CB1 receptor agonists into the dlPAG of rats has been
shown to induce antinociceptive responses [33] and electric
stimulation of the dorsal and lateral columns induces
antinociceptionviaactivationofCB1receptorsaccompanied
by local AEA release [34]. Furthermore, subcutaneous
formalininjection,apainfulstimulus,substantiallyincreased
the release of AEA in the PAG [34, 35].
Concerning the possible involvement of PAG-endo-
cannabinoid system on modulation of anxiety-like behav-
iors, an initial study showed that local administration
of HU210, a potent CB1 agonist, attenuated the ﬂight
responses induced by dPAG injections of the excitatory
amino acid D,L-homocysteic acid (see [36, Table 2]). In a
subsequent study, where the injections were restricted to
the dorsomedial PAG, HU210 decreased hyperlocomotionNeural Plasticity 3
Table 1: Eﬀects of cannabinoids and drugs that interfere with the endocannabinoid system in animal models predictive of anxiolytic- or
anxiogenic-like activity. (AEA: AEA; Δ9-THC: Δ9-tetrahydrocannabinol; CBD: cannabidiol; EPM: elevated plus-maze; EXM: elevated X-
maze; EZM: elevated zero-maze; VCT: Vogel conﬂict test; FC: fear conditioning; DLT: dark-light test; SI: social; NSF: novelty-suppressed
feeding interaction.)
Drug Test
Dose (species)
Reference
Anxiolytic-like eﬀects Anxiogenic-like eﬀects
Phytocannabinoids
Δ9-THC
EPM 10–20mg/kg (mouse) [37]
EPM 1–10mg/kg (rat) [37]
DLT 0.3mg/kg (mouse) 0.5mg/kg (mouse) [38]
DLT 0.3mg/kg (mouse) [39]
EPM 1–10mg/kg (mouse) [40]
EPM 0.075–0.75mg/kg (rat) [41]
EPM 0.5–2.5mg/kg (rat) [42]
DLT 1.25–2.5mg/kg (rat) [42]
EPM 0.075–1.5; 3∗ mg/kg (rat) [43]
CBD
EPM 1–10mg/kg (mouse) [37]
EPM 2.5–10; 20∗ mg/kg (rat) [44]
EPM 5mg/kg (rat) [45]
VCT 10 mg/kg (rat) [46]
FC 10mg/kg (rat) [47]
CB1 agonists
HU210
EXM 25μg/kg, 10 days (rat) [48]
NSF 100μg/kg/day–10 days (rat) [49]
EPM 10μg/kg (rat) 50μg/kg (rat) [50]
WIN-55212
EPM 1–3mg/kg (mouse) [51]
EPM 1–3; 10∗ mg/kg (mouse) [40]
EPM 1–3mg/kg (mouse) 1–3mg/kg (rat) [52]
CP55940
EPM 75–125μg/kg (rat) [53]
EPM 75μg/kg (rat) [54]
EPM 1μg/kg (rat) 50μg/kg (rat) [55]
EPM 2.5–5μg/kg (rat) 40μg/kg (rat) [56]
SI 40μg/kg (rat) [57]
EPM 0.1–0.3mg/kg (mouse) [40]
AEA EPM 10mg/kg (mouse) [58]
DLT 0.3mg/kg (rat) [59]
AEA uptake inhibitor
AM404
EPM 5mg/kg (rat) [60]
EPM 1–3; 10∗ mg/kg (mouse) [40]
EPM 0.75–1.25mg/kg (rat) [37]
AEA metabolism inhibitors
URB597
EZM 0.1mg/kg (rat) [61]
EPM 0.1–0.3mg/kg (mouse) [40]
EPM 0.1mg/kg (mouse) [62]
DLT 0.1–0.3mg/kg (rat) [55]
EPM 1mg/kg (mouse) [63]
AACOCF3 DLT 4mg/kg (mouse) [64]4 Neural Plasticity
Table 1: Continued.
Drug Test
Dose (species)
Reference
Anxiolytic-like eﬀects Anxiogenic-like eﬀects
CB1 antagonists
Rimonabant
EPM 3mg/kg (rat) [65]
EPM 3mg/kg (rat) [53]
EPM 3mg/kg (mouse) [66]
VCT 0.3–3mg/kg (rat) [67]
EPM 10mg/kg (rat) [67]
EPM 3–10mg/kg (mouse) [40]
AM251
EPM 3mg/kg (mouse) [51]
EPM 1.3–3mg/kg (mouse) [68]
EPM 3–10mg/kg (mouse) [40]
EPM 1–3mg/kg (mouse) [52]
TRPV1 agonists
Olvanil EPM 5mg/kg (rat) [69]
TRPV1 antagonists
Capzasepine EPM 1–10μg/kg (rat) [69]
∗ Bell-shaped dose-response curve.
induced by aversive ultrasound stimulation, but failed to
changefreezingresponses.Moreover,HU210eﬀectswerenot
entirely blocked by previous local injection of a CB1 receptor
antagonist [70].
Considering these initial results, we decided to further
investigate a possible inﬂuence of the PAG-endocannabinoid
system on anxiety-like behaviors in rats submitted to diﬀer-
ent animal models of anxiety (Table 2). First, we showed that
AEA injected into the dlPAG increased the exploration of the
open arms of the elevated plus maze (EPM) [71], a model
basedonanaturalconﬂictbetweenexploratorybehaviorand
innate fear of open spaces. The eﬀects of AEA were similar
to those observed with classical anxiolytic benzodiazepines
[72] and were blocked by previous treatment with AM251, a
CB1 receptor antagonist. These eﬀects were also potentiated
by previous treatment with AM404, an inhibitor of AEA
uptake/metabolism. AM404 by itself, however, was without
eﬀect in this model. AEA produced an inverted U-shaped
dose-response curve, with higher doses being ineﬀective
[71].
To conﬁrm a possible anticonﬂict eﬀect of AEA in the
dlPAG, we used the Vogel conﬂict test (VCT) [73], an animal
model of anxiety not based on innate fear but instead on
suppressionofpunishedresponseslearnedduringthetest.In
this model, water-deprived rodents are exposed to a conﬂict
between licking the spout of a bottle containing water and
receiving a mild shock on the tong [74]. Anxiolytics that
potentiate the action of γ-aminobutyric acid such as the
benzodiazepines typically increase the number of punished
licks [75]. AEA also induced anxiolytic-like eﬀects in the
VCT at the same dose range observed in the EPM (Table 2).
Diﬀerent from the results obtained in the latter model,
AM404 was also able to increase the number of punished
licks (Table 2). Although the causes of these contradictory
results are not clear, they could involve the distinct animal
models of anxiety employed. Brain endocannabinoids have
b e e np r o p o s e dt oa c ta sa“ s t r e s sb u ﬀer system” [76],
recruitedbyhighlydemandingsituations.Itwaspossiblethat
the VCT, by involving pain and water deprivation, engages
the endocannabinoid system in the dlPAG to a greater extent
than the EPM. Actually, as discussed above, painful stimuli
such as those used in the VCT have already been showed to
increase AEA in this region [77].
We have further investigated this eﬀect by intra-dlPAG
administration of AEA and AM404 in rats submitted to
a contextual fear conditioning paradigm, an animal model
that also involves pain exposure [78]. Animals re-exposed to
an environment where they had being previously submitted
to an aversive stimulation, such as electrical footshocks,
show behavioral and cardiovascular changes characterized
by immobility (freezing) and mean arterial pressure (MAP)
and heart rate (HR) increases [79, 80]. Although electrical
or chemical stimulation of the dorsal portion of PAG is
usually related with ﬂight reactions, it can also produce
freezingresponsesandincreasedcardiovascularactivity[26].
Re-exposure to an aversively conditioned context increases
neuronal activity in the PAG [81, 82], and PAG lesions block
freezing to aversively conditioned stimulus [83, 84]. dlPAG
microinjection of AEA or AM404 blocked the expression
of the conditioned aversive responses [78]. This eﬀect was
inhibited by local pretreatment with AM251, reinforcing the
involvement of CB1 receptors.
Altogether, these results suggest that the endocannabi-
noid system in the dlPAG can modulate responses to aversive
stimuli. The mechanisms of these eﬀects are still unclear.
Using brain slices of the rat PAG, Vaughan et al. [85]
showed that cannabinoids act via CB1 receptors to inhibit
GABAergic and glutamatergic synaptic transmission. The
eﬃcacy of endogenous cannabinoids was limited by uptake
and breakdown since AEA was only able to inhibit evokedNeural Plasticity 5
Table 2: Eﬀects of Cannabinoid-related drugs injected into the PAG of rats submitted to animal models of anxiety-related behaviors.
(AEA: anandamide; ACEA: arachidonyl-2-chloro-ethylamide; CBD: cannabidiol; EPM: elevated plus-maze; VCT: Vogel conﬂict test; CFC:
contextual fear conditioning; dlPAG: dorsolateral PAG; dPAG: dorsal (dorsolateral + dorsomedial) PAG; dmPAG: dorsomedial PAG; unpub:
unpublished data.)
Drug PAG column Test Doses tested Eﬀect (eﬀective
dose) Ref.
Phytocannabinoids CBD dlPAG EPM, VCT 15–60nmol Anxiolytic
(30nmol∗) [86]
Endocannabinoids AEA dlPAG
EPM 0.05–50pmol Anxiolytic
(5pmol∗,1) [71]
VCT 5pmol Anxiolytic [73]
CFC 5pmol Anxiolytic [78]
CB1 receptor agonists
ACEA dlPAG EPM 0.05–5pmol Anxiolytic
(0.05pmol∗) [71]
HU210 dPAG dPAG chemical
stimulation 0.1–5μg Attenuated ﬂight
responses (0.1–5μg) [36]
HU210 dmPAG
Ultrasound-
induced
hyperlocomotion
and freezing
5μg
Decreased
hyperlocomotion,
but increased
freezing∗∗
[70]
CB1 receptor antagonist
AM251 dlPAG EPM, VCT, CFC 1–300pmol
No eﬀect by itself,
but blocked AEA
and AM404
anxiolytic eﬀects
[71, 73,
78]
Rimonabant dPAG
Ultrasom-induced
hyperlocomotion
and freezing
30μgN o e ﬀect by itself [70]
AEA uptake inhibitor AM404 dlPAG
EPM 0.5–50pmol
No eﬀect by itself;
potentiated the
anxiolytic eﬀect of
AEA
[71]
VCT 50pmol Anxiolytic [73]
CFC 50pmol Anxiolytic [78]
AEA metabolism inhibitor URB597 dlPAG VCT 0.01–0.1nmol Anxiolytic
(0.01pmol∗) [73]
TRPV1 antagonists Capsazepine dlPAG EPM, VCT 10–60nmol Anxiolytic
(60nmol)+ [87]
∗ Bell-shaped dose-response curve. Anxiolytic eﬀect blocked by AM251 (100pmol) and potentiated by AM404 (50pmol).
+Capsazepine 10nmol turned the higher, ineﬀective dose of CBD (60nmol) into an anxiolytic one in the EPM [85].
∗∗Not blocked by rimonabant 30μg.
inhibitory postsynaptic currents in the presence of the AT
inhibitor, AM404. Several studies indicate that GABA- and
glutamate-mediated neurotransmissions in the dPAG play
opposite roles. While the former tonically inhibits defensive
responses, the latter facilitates them [26]. Thus, CB1-
mediated inhibitory eﬀects on these two neurotransmitter
systems could be one of the explanations for the observed
bell-shaped dose-response curve induced by AEA in this
region as well as the contradictory results regarding the
eﬀects of cannabinoids on anxiety (see Table 1 and text
bellow for a discussion on the possible involvement of
TRPV1 receptors).
ThesemechanismsmayexplaintheeﬀectsinthePAG,yet
they do not necessarily apply to other brain regions. In some
areas, the levels of CB1 receptor expression can be higher
in GABAergic (particularly in cholecystokinin-containing
basket cells) as compared to glutamatergic neurons, with
cannabinoideﬀectsfavoringimpairmentofinhibitorymech-
anisms mediated by the former neuronal population [16].
However,itremainstobefurtherinvestigatedhowtheseneu-
ral subpopulations contribute to speciﬁc behavioral eﬀects
of cannabinoids. In addition, GABAergic and glutamatergic
neurons may have diﬀerent sensitivity to CB1 agonists or
antagonists depending on the species under investigation.
For instance, Haller et al. [52]o b s e r v e do p p o s i t ee ﬀects in
mice and rats tested with the same doses of a cannabinoid
in models of anxiety-like behavior (see Table 1). Inhibitory
and excitatory currents were diﬀerentially aﬀected in the
hippocampi of these species, providing a possible basis
for the discrepancies in the behavioral responses. Since
we have employed rats as subjects in all our experiments,
studies in other species could further consolidate our6 Neural Plasticity
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Figure 1: Possible eﬀects of cannabinoids in the dlPAG. Glutamatergic inputs from forebrain structures such as the dorsomedial part of the
ventromedialhypothalamicnucleus(dmVMH)anddorsalpremammilaryhypothalamicnucleus(PmD)activatealocalneuralsubstratethat
mediatesdefensiveresponses[88].ThissubstrateisunderGABAergicandserotonergicinhibitoryinﬂuence[26].ActivationofCB1receptors
by cannabinoids such as AEA interferes with presynaptic glutamate (Glu) and GABA (Ga) neurotransmitter release. CB1-mediated decrease
of glutamate release would promote anxiolytic-like eﬀects. Activation of TRPV1 presynaptic receptors, on the other hand, would produce
opposite eﬀects. The anxiolytic eﬀects of cannabidiol (CBD), a nonpsychotomimetic cannabinoid, in the dlPAG are not mediated by CB1
receptors, but probably involve activation of postsynaptic 5HT1A receptors. The bell-shaped dose-response curves observed with AEA and
CBD may depend on activation of TRPV1 receptors. Regarding AEA, a presynaptic decrease of GABA release could also be related to this
eﬀect.
hypothesis that glutamatergic and GABAergic inhibitions
would mediate anxiolytic- and anxiogenic-like eﬀects of
cannabinoids, respectively. For a more extensive discussion
on the relevance of diverse neural subpopulations for the
eﬀects of cannabinoids, see [89].
4.Cannabidiol
Cannabidiol (CBD) is a major nonpsychotomimetic con-
stituent of Cannabis sativa that is able to antagonize the
anxiogenic and psychotomimetic eﬀects of high doses of
Δ9-THC [90, 91]. It also promotes anxiolytic-like eﬀects in
several animal models (see [44–47], Table 1). In addition,
CBD induces anxiolytic eﬀects in healthy volunteers in the
simulated public speaking test, a model of clinical anxiety,
and in subjects submitted to a functional imaging analysis
study [92, 93]. However, as commonly seem with other
cannabinoids in animal models of anxiety, experiments with
CBDyieldbell-shapeddose-responsecurves,lowdosesbeing
anxiolytic, and higher doses being ineﬀective [44]. The
mechanisms for these actions remain poorly understood.
CBD has low aﬃnity for CB1 or CB2 receptors and could
facilitate the endocannabinoid signalling by inhibition of
AEA uptake or its enzymatic hydrolysis. It can also act as an
agonist of TRPV1 or 5HT1A receptors [94, 95].
Considering that the PAG, in addition to CB1 [14],
also expresses a signiﬁcant number of TRPV1 and 5HT1A
receptors [96, 97], we decided to verify if this region
could be related to the eﬀects of CBD. We found that
CBD microinjections into the dlPAG produced anxiolytic-
like eﬀects in rats submitted to the EPM or the VCT
[86]( Table 2). The eﬀects in the EPM, however, also
showed a bell-shaped dose-response curve, but were not
blocked by previous local administration of AM251 [86],
employed at the same dose that was able to antagonize the
anxiolytic-like eﬀects of AEA and AM404 (Table 2). TheNeural Plasticity 7
anxiolytic-like eﬀects of CBD, however, were prevented by
WAY100635, an antagonist of 5HT1A receptors. Activation
of these Gi-coupled-receptors enhances K+ currents and
inhibits adenylyl cyclase activity [98]. They act as inhibitory
autoreceptorsinserotonergicneuronsintheraphenucleibut
are also localized postsynaptically in several brain regions,
including the PAG, amygdala, hippocampus, and frontal
cortex. Actually, the PAG receives serotonergic projections
from the dorsal raphe nuclei, and local activation of 5HT1A
receptors promotes the control of anxiety states and the
hypothalamus-pituitary-adrenal axis during stress responses
[99]. Thus, 5HT1A receptors located in the PAG are possibly
involved in the anxiolytic-like eﬀects of CBD, a hypothesis
corroboratedbyseveralstudiesshowingthatagonistsofthese
receptors produce anxiolytic eﬀects in the PAG [100, 101].
5.TRPV1ReceptorsMethods
TRPV1 receptors belong to a large family of calcium-
permeable cation channels [102]. They can be activated
by elevation in temperature, pH decrease, or by exogenous
ligands such as capsaicin, the pungent ingredient of red hot
chilli peppers [103, 104]. They have been related to pain
transmission and inﬂammatory responses in the peripheral
nervous system. In addition to environmental stimuli, endo-
cannabinoids such as AEA and N-arachidonyldopamine can
also activate TRPV1 receptors. As a consequence, they can
also be denominated endovanilloids [104, 105].
TRPV1 receptors are expressed in various brain regions
related to anxiety, including the PAG [106, 107], where they
can regulate glutamate release. Corroborating this proposal,
local infusion of capsaicin produces antinociception by
increasing glutamate release in this region [108]. In addition,
activation of presynaptic TRPV1 receptors produced an
excitatory eﬀect in the ﬁring activity of dlPAG neurons
[109]. Glutamate is the main excitatory neurotransmitter
in the central nervous system, and the injection of NMDA
antagonist receptors into the dlPAG promotes anxiolytic
eﬀects in the EPM and VCT [110].
Few studies, however, have investigated the role of
TRPV1 in anxiety. Systemic administration of capsazepine,
a TRPV1 antagonist, induced anxiolytic-like eﬀects in rats
s u b m i t t e dt ot h eE P M( Table 1)[ 69]. More recently, Marsch
et al. [111] demonstrated that TRPV1-deﬁcient mice show
decreased anxiety in the EPM and light-dark test. Accord-
ingly, the dual FAAH/TRPV1 blocker N-arachidonoyl-
serotonin is able to induce CB1-mediated anxiolytic-like
eﬀects more potently than selective blockers of FAAH or
TRPV1, further suggesting opposite roles for CB1 and
TRPV1 receptors [112].
To further investigate the role of TRPV1 on anxiety
modulation, we veriﬁed the eﬀects of intra-dlPAG injection
of capsazepine in rats submitted to the EPM and VCT.
This drug decreased anxiety-like behaviors in both models
(Table 2), suggesting that TRPV1 receptors facilitate anxiety
responses in the PAG. The fact that AEA and CBD can also
activateTRPV1receptors[94,104,105]couldhelptoexplain
the bell-shaped dose-response curves usually found with
these compounds regarding their anxiolytic eﬀects (Tables
1 and 2). In agreement with this proposal, it was recently
showedthatcapsazepineblockstheanxiogeniceﬀectsofhigh
doses of AEA in the prefrontal cortex [113]. It remained
to be tested if similar eﬀects could occur in the dlPAG.
In an initial study, we conﬁrmed this possibility, showing
that intra-dlPAG pretreatment with an ineﬀective dose of
capsazepine was able to turn the higher, ineﬀective dose of
the CBD into an anxiolytic one (Table 2).
6. Conclusions
The pieces of evidence revised above suggest that the
PAG, particularly its dorsolateral column, is involved in the
modulatory eﬀects of cannabinoids on defensive responses.
This does not mean that the PAG is the only or the most
relevant structure accounting for the antiaversive properties
of cannabinoids. Other authors have also identiﬁed brain
sites where CB1 receptor activation induces anxiolytic-like
eﬀects. Injection of low doses of Δ9-THC either in the
ventral hippocampus (5μg) or in the prefrontal cortex
(10μg) resulted in anxiolytic-like eﬀects; whereas in the
amygdala (1μg), opposite results were reported [114]. An
early work has also shown anxiogenic-like eﬀect of Δ9-THC
in this brain region [115] Moreover, intraprefrontal cortex
injection of low or high doses of methanandamide induces
CB1-mediated anxiolytic- or TRPV1-mediated anxiogenic-
like eﬀects, respectively [113]. Other authors have also
investigated brain sites mediating nociceptive responses,
antidepressive-like activity, and rewarding eﬀects of cannabi-
noids [89].
In conclusion, local administration of CB1 agonists into
the dlPAG produces anxiolytic-like eﬀects in several animal
models. These eﬀects are prevented by AM251, indicating
that they are being mediated by activation of CB1 receptors,
possibly by presynaptic inhibition of glutamate release (see
Figure 1). Results with AM404, an AEA metabolism/uptake
inhibitor, also suggest that local synthesis of endocannabi-
noidsinthedlPAGcanmodulatedefensiveresponses,atleast
under high-aversive conditions. The results also showed that
thedlPAGcouldbeinvolvedinthereportedanxiolyticeﬀects
of CBD, a nonpsychotomimetic phytocannabinoid. This
compound, however, appears to act by activating 5HT1A
receptors (Figure 1). Finally, activation of vanilloid TRPV1
receptors in the dlPAG seems to facilitate defensive responses
(Figure 1) and may be, in part, responsible for the bell-
shaped dose-response curves of the anxiolytic eﬀects of AEA
and CBD. A balance between CB1- and TRPV1-activations is
apossiblemechanismthroughwhichendogenousAEAcould
c o n t r o la v e r s i v er e s p o n s e s .
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